Myxoid Liposarcoma, Synovial Sarcoma
Conditions
Brief summary
The purpose of this expanded access protocol (EAP) is to provide controlled access to Afamitresgene autoleucel, suspension for intravenous infusion that does not meet the commercial release specification (NC afami-cel). This EAP will be conducted at authorized treatment centers where TECELRA® is being administered and where the EAP is approved to be conducted. Patients who are prescribed TECELRA® , sign the informed consent form, and meet all entry criteria will be eligible to participate in this protocol.
Interventions
GENETICNon-conforming afamitresgene autoleucel
Non-conforming afamitresgene autoleucel, suspension for intravenous infusion (NC afami-cel), single dose administration
Sponsors
USWM CT, LLC
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patient must provide written informed consent prior to participating in this protocol * Patient must have been prescribed TECELRA® * Patient's commercially manufactured product does not meet the commercial release specification * Repeat manufacture is not feasible or is not clinically appropriate per Investigator assessment in consultation with per consultation with USWM CT * Repeat leukapheresis is not feasible or is not clinically appropriate per Investigator assessment * The Investigator has confirmed a favorable benefit:risk profile, following sponsor evaluation of the NC afami-cel, and deems proceeding with treatment under this EAP is in the best interest of the patient * Patient deemed medically fit and stable to receive NC afami-cel per Investigator assessment * Female patients with reproductive potential must have a negative serum or urine pregnancy test within 7 days of initiating lymphodepleting chemotherapy
Exclusion criteria
* Patient has contraindication(s) as per the TECELRA® USPI * Do not use TECELRA® in adults who are heterozygous or homozygous for HLA-A\*02:05P
Countries
United States
Contacts
CONTACTClinical Scientist
Outcome results
None listed